Monday, August 22, 2011 (Last Updated: 08/23/2011)
MONDAY, Aug. 22 (HealthDay News) -- The relative survival of children and adults with medulloblastomas and primitive neuroectodermal tumors (PNETs) is affected by the length of follow-up, with adults having a worse prognosis four years after diagnosis, according to a study published online Aug. 11 in Cancer.
Nicolas R. Smoll, M.D., from Monash University in Churchill, Australia, evaluated the impact of medulloblastomas/PNETs and relative survival on the U.S. population, focusing on the age differences of the patients. Cumulative relative survival (CRS) was estimated from Surveillance, Epidemiology, and End Results expected mortality data, and Ederer II method for expected survival estimation, using crude, period, and longitudinal period approaches for patients diagnosed with all medulloblastoma subtypes and PNETs. Rational scheduling protocols were constructed for follow-up between 2001 and 2006.
The investigators found that the five-year CRS period for all patients was 69 percent. After four years of follow-up, excess hazard rates projected a worse overall prognosis for adults. Over the past 25 years, the five-year and 10-year CRS improved a minimum of 11 percent in children, adolescents, and adults.
"The survival difference between children, adolescents, and adults with medulloblastomas and PNETs depended on the length of follow-up," the author writes. "Differences in survival between children and adults emerged only four years after diagnosis, and adults fared worse."
Hematology & Oncology
Copyright © 2011 HealthDay. All rights reserved.